Entrada Therapeutics Stock (NASDAQ: TRDA)

Entrada Therapeutics

ENTRADA THERAPEUTICS INC

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Munich,,Bavaria,,Germany,-,March,31,2023:,Entrada,Therapeutics,Is

Biotech

News

Health Care

General

TRDA

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscular dystrophy patients.

FDA Clears Entrada Therapeutics&#39; Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy

Earnings

Earnings Beats

Large Cap

Small Cap

Management

Markets

Analyst Ratings

Trading Ideas

IMTX

AstraZeneca (NASDAQ: AZN) announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain patients with primary advanced or recurrent endometrial cancer, also known as uterine cancer.

AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer

Penny Stocks

Evotec (NASDAQ: EVO) achieved substantial progress in its strategic partnership with Bristol Myers Squibb (NYSE: BMY) relating to building a molecular glue-based pipeline.

Evotec Rises 12% on $75M Milestone Payment From BMY

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics Inc

Press Releases

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

AZTA

Absci

Abivax

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Astria Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Candel Therapeutics

Celcuity

Erasca

Heron Therapeutics

Keros Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sana Biotechnology

Solid Biosciences

Stoke Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tourmaline Bio

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

Verastem

HC Wainwright & Co.

Roth MKM

Oppenheimer

Goldman Sachs

Comments

Entrada Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga